Bausch Health Companies Inc. Goodwill, Foreign Currency Translation Gain (Loss)
Bausch Health Companies Inc. (BHC) reported Goodwill, Foreign Currency Translation Gain (Loss) of $57.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-07-30
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-06-30 was $19.00M.
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-03-31 was $38.00M.
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-12-31 was -$14.00M, a 112.61% decline year-over-year.
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-09-30 was $11.00M.
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for fiscal 2024 was $125.00M.
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for fiscal 2023 was -$98.00M.
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for fiscal 2022 was -$91.00M.
- Bausch Health Companies Inc. goodwill, foreign currency translation gain (loss) for fiscal 2021 was -$118.00M, a 200.85% decline from fiscal 2020.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $57.00M 10-Q · filed 2026-07-30 | $43.00M derived: sum of 3 quarters · filed 2026-07-30 | $54.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $38.00M 10-Q · filed 2026-04-30 | $24.00M derived: sum of 2 quarters · filed 2026-07-30 | $35.00M derived: sum of 3 quarters · filed 2026-07-30 | -$110.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | -$14.00M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | -$3.00M derived: sum of 2 quarters · filed 2026-07-30 | -$148.00M derived: sum of 3 quarters · filed 2026-07-30 | -$214.00M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$134.00M derived: sum of 2 quarters · filed 2025-10-30 | -$200.00M 10-Q · filed 2025-10-30 | -$89.00M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2025-06-30 | -$145.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$211.00M 10-Q · filed 2025-07-31 | -$100.00M derived: sum of 3 quarters · filed 2026-02-19 | -$142.00M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2025-03-31 | -$66.00M 10-Q · filed 2025-05-01 | $45.00M derived: sum of 2 quarters · filed 2026-02-19 | $3.00M derived: sum of 3 quarters · filed 2026-02-19 | $36.00M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-12-31 | $111.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $69.00M derived: sum of 2 quarters · filed 2026-02-19 | $102.00M derived: sum of 3 quarters · filed 2026-02-19 | $125.00M 10-K · filed 2026-02-19 | |
| 2024-09-30 | -$42.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$9.00M derived: sum of 2 quarters · filed 2024-10-31 | $14.00M 10-Q · filed 2024-10-31 | -$73.00M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2024-06-30 | $33.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $56.00M 10-Q · filed 2024-08-01 | -$31.00M derived: sum of 3 quarters · filed 2025-02-20 | $31.00M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2024-03-31 | $23.00M 10-Q · filed 2024-05-02 | -$64.00M derived: sum of 2 quarters · filed 2025-02-20 | -$2.00M derived: sum of 3 quarters · filed 2025-02-20 | -$45.00M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-12-31 | -$87.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$25.00M derived: sum of 2 quarters · filed 2025-02-20 | -$68.00M derived: sum of 3 quarters · filed 2025-02-20 | -$98.00M 10-K · filed 2025-02-20 | $98.00M 10-K · filed 2024-02-22 |
| 2023-09-30 | $62.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $19.00M derived: sum of 2 quarters · filed 2023-11-02 | -$11.00M 10-Q · filed 2023-11-02 | -$313.00M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2023-06-30 | -$43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$73.00M 10-Q · filed 2023-08-03 | -$375.00M derived: sum of 3 quarters · filed 2024-02-22 | -$272.00M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2023-03-31 | -$30.00M 10-Q · filed 2023-05-04 | -$332.00M derived: sum of 2 quarters · filed 2024-02-22 | -$229.00M derived: sum of 3 quarters · filed 2024-02-22 | -$151.00M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-12-31 | -$302.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$199.00M derived: sum of 2 quarters · filed 2024-02-22 | -$121.00M derived: sum of 3 quarters · filed 2024-02-22 | -$91.00M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $103.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $181.00M derived: sum of 2 quarters · filed 2022-11-03 | $211.00M 10-Q · filed 2022-11-03 | -$5.00M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2022-06-30 | $78.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $108.00M 10-Q · filed 2022-08-09 | -$108.00M derived: sum of 3 quarters · filed 2023-02-23 | -$58.00M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2022-03-31 | $30.00M 10-Q · filed 2022-05-10 | -$186.00M derived: sum of 2 quarters · filed 2023-02-23 | -$136.00M derived: sum of 3 quarters · filed 2023-02-23 | -$178.00M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-12-31 | -$216.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$166.00M derived: sum of 2 quarters · filed 2023-02-23 | -$208.00M derived: sum of 3 quarters · filed 2023-02-23 | -$118.00M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $8.00M derived: sum of 2 quarters · filed 2021-11-02 | $98.00M 10-Q · filed 2021-11-02 | $231.00M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | -$42.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $48.00M 10-Q · filed 2021-08-03 | $181.00M derived: sum of 3 quarters · filed 2023-02-23 | $105.00M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $90.00M 10-Q · filed 2021-05-04 | $223.00M derived: sum of 2 quarters · filed 2023-02-23 | $147.00M derived: sum of 3 quarters · filed 2023-02-23 | $97.00M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $133.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $57.00M derived: sum of 2 quarters · filed 2023-02-23 | $7.00M derived: sum of 3 quarters · filed 2023-02-23 | $117.00M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$76.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | -$126.00M derived: sum of 2 quarters · filed 2020-11-03 | -$16.00M 10-Q · filed 2020-11-03 | -$92.00M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-06-30 | -$50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $60.00M 10-Q · filed 2020-08-06 | -$16.00M derived: sum of 3 quarters · filed 2022-05-11 | $74.00M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-03-31 | $110.00M 10-Q · filed 2020-05-07 | $34.00M derived: sum of 2 quarters · filed 2022-05-11 | $124.00M derived: sum of 3 quarters · filed 2022-05-11 | $85.00M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2019-12-31 | -$76.00M derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $14.00M derived: sum of 2 quarters · filed 2022-05-11 | -$25.00M derived: sum of 3 quarters · filed 2022-05-11 | -$1.00M 8-K · filed 2022-05-11 | |
| 2019-09-30 | $90.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $51.00M derived: sum of 2 quarters · filed 2019-11-04 | $75.00M 10-Q · filed 2019-11-04 | ||
| 2019-06-30 | -$39.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$15.00M 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $24.00M 10-Q · filed 2019-05-06 | ||||
| 2018-12-31 | -$127.00M 8-K · filed 2021-05-04 | $127.00M 10-K · filed 2019-02-20 | |||
| 2018-09-30 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-06 | $142.00M 10-Q · filed 2018-11-06 | $88.00M derived: sum of 3 quarters · filed 2018-11-06 | $113.00M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-06-30 | $149.00M 10-Q · filed 2018-08-07 | $95.00M derived: sum of 2 quarters · filed 2018-11-06 | $120.00M derived: sum of 3 quarters · filed 2020-02-19 | $190.00M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-03-31 | -$54.00M 10-Q · filed 2018-11-06 | -$29.00M derived: sum of 2 quarters · filed 2020-02-19 | $41.00M derived: sum of 3 quarters · filed 2020-02-19 | $164.00M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2017-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $95.00M derived: sum of 2 quarters · filed 2020-02-19 | $218.00M derived: sum of 3 quarters · filed 2020-02-19 | $286.00M 10-K · filed 2020-02-19 | |
| 2017-09-30 | $70.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $193.00M derived: sum of 2 quarters · filed 2017-11-07 | $261.00M 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | $123.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $191.00M 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $68.00M 10-Q · filed 2017-05-09 | ||||
| 2015-12-31 | -$308.00M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |